Hadrian raised $1.37B at a $7.87B valuation to scale AI-run factories making parts for rockets, subs, and jets — its price tag quintupled since January.
SK Hynix's board just approved 54 trillion won ($38B) for two new fabs that won't ship a chip until 2029 — a massive bet that the AI memory shortage is permanent.
Bending Spoons is buying Airtable for $1.285 billion in all cash — about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
Pathos AI committed up to $2.2 billion to license cancer drugs from Alphamab and AstraZeneca without inventing a single molecule. Inside the bet that AI's real job is picking patients, not chemistry.
Valar Atomics raised $1B at a $6B valuation, led by Sequoia, to mass-produce small nuclear reactors for AI data centers.
Socure raised $156M at a $5.2B valuation and bought agentic-AI startup Fravity to fight machine-speed fraud with AI agents of its own.
🔥 Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Bending Spoons is buying Airtable for $1.285 billion in all cash — about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
AusperBio raised $120M to push AHB-137, an antisense drug that cleared hepatitis B in 68% of a small trial, toward the first functional cure for a disease 240 million people live with.
